Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MicroPort NeuroScientificHKSE:02172 -1.20%93 ROE % is 10.44% as of Dec. 2025, which is 30% below its 10-year median of 15.01. GuruFocus rates HKSE:02172 with a GF Score™ of 93/100 and a GF Value™ of HK$13.19 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 800 Medical Devices & Instruments companies, MicroPort NeuroScientific ranks better than 75.87% on this metric.
The historical rank and industry rank for MicroPort NeuroScientific's ROE % or its related term are showing as below:
HKSE:02172'
s ROE % Range Over the Past 10 Years
Min: -3.4 Med: 15.01 Max: 27.93
Current: 10.67
During the past 7 years, MicroPort NeuroScientific's highest ROE % was 27.93%. The lowest was -3.40%. And the median was 15.01%.
HKSE:02172's ROE % is ranked better than 75.87% of 800
companies
in the Medical Devices & Instruments industry
Industry Median: 2.645
vs HKSE:02172: 10.67
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MicroPort NeuroScientific's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MicroPort NeuroScientific ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MicroPort NeuroScientific's ROE % distribution charts can be found below:
* The bar in red indicates where MicroPort NeuroScientific's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
MicroPort NeuroScientific (HKSE:02172) has a ROE % of 10.44% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on MicroPort NeuroScientific and its competitors. This is 30% below median its historical median of 15.01. According to the industry distribution chart, MicroPort NeuroScientific ranks #193 out of 800 companies in the Medical Devices & Instruments industry, placing it in the top 24.1%.
Is MicroPort NeuroScientific's ROE % too high?
MicroPort NeuroScientific's current ROE % of 10.44% is 30% below median its 10-year median of 15.01. The Medical Devices & Instruments industry median ROE % is 2.65. MicroPort NeuroScientific's value of 10.44% is 294.7% above this industry median. Based on the distribution chart, MicroPort NeuroScientific ranks #193 out of 800 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MicroPort NeuroScientific has a GF Score™ of 93/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MicroPort NeuroScientific's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MicroPort NeuroScientific ranks #193 out of 800 companies for ROE %. This places MicroPort NeuroScientific in the top 24% of its industry — outperforming the majority of peers. The industry median ROE % is 2.65. MicroPort NeuroScientific's value of 10.44% is 294.7% above this benchmark. While the company's 10-year median is 15.01 vs. the industry median of 2.65, MicroPort NeuroScientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.65, based on 800 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MicroPort NeuroScientific's current ROE % of 10.44% is 294.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on MicroPort NeuroScientific and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MicroPort NeuroScientific's current ROE % is 10.44%, which is 30% below median its own 10-year median of 15.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MicroPort NeuroScientific stock overvalued right now?
Based on GuruFocus' analysis, MicroPort NeuroScientific (HKSE:02172) is currently considered Possible Value Trap. The stock's GF Value™ is HK$13.19, compared to a current price of HK$9.02 — trading 31.6% below its estimated fair value. The current ROE % is 10.44%, which is 30% below median its 10-year median of 15.01 and 294.7% above the Medical Devices & Instruments industry median of 2.65. MicroPort NeuroScientific's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For MicroPort NeuroScientific (HKSE:02172), the current ROE % is 10.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MicroPort NeuroScientific (HKSE:02172) Overvalued in 2026?
Based on GuruFocus' analysis, MicroPort NeuroScientific stock appears to be undervalued.
The current stock price of HK$9.02 is trading 31.6% below its estimated GF Value™ of HK$13.19.
GuruFocus considers MicroPort NeuroScientific to be Possible Value Trap.
Key valuation signals for HKSE:02172:
ROE %: 10.44% (30% below median its 10-year median of 15.01)
GF Value™: HK$13.19 vs. price of HK$9.02 (31.6% below fair value)
Industry Position: 294.7% above the Medical Devices & Instruments median (#193 of 800)
No single metric tells the full story. See the HKSE:02172 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MicroPort NeuroScientific Corp is in the neuro-interventional medical device industry, dedicated to providing solutions for physicians and patients. The company boasts a comprehensive portfolio of approved therapeutic products covering all of three main areas of neurovascular disease, namely hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke. The company generates almost all of its revenue from the sale of medical devices. Geographically, the company generates the majority of its revenue from the PRC region, and also has operations in Israel.
93GF Score
Get the complete analysis for HKSE:02172
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02172 has been successfully added to your 
